| Dr Faisal M Almufarrej, MD | |
|
3901 Beaubien St, Detroit, MI 48201-2119 | |
| (313) 745-0247 | |
| (313) 993-8783 |
| Full Name | Dr Faisal M Almufarrej |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 21 Years |
| Location | 3901 Beaubien St, Detroit, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437395308 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Physician Group | 8628087681 | 345 |
News Archive
Johns Hopkins Kimmel Cancer Center scientists report that sharp rises in levels of reactive oxygen molecules, and the inflammation that results, trigger biochemical changes that silence genes in a pattern often seen in cancer cells. The researchers confirmed this gene-silencing effect in mice that develop inflammation-induced colon cancer.
A selection of health policy stories from Florida, Connecticut, New York, Michigan, Louisiana, Pennsylvania and Arkansas.
Danish researchers are claiming that the benefits of breast cancer screening are questionable and that mammograms can lead to women being given unnecessary and harmful treatment.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.
› Verified 8 days ago
| Entity Name | Barbara Ann Karmanos Cancer Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225022288 PECOS PAC ID: 3870407901 Enrollment ID: O20031113000601 |
News Archive
Johns Hopkins Kimmel Cancer Center scientists report that sharp rises in levels of reactive oxygen molecules, and the inflammation that results, trigger biochemical changes that silence genes in a pattern often seen in cancer cells. The researchers confirmed this gene-silencing effect in mice that develop inflammation-induced colon cancer.
A selection of health policy stories from Florida, Connecticut, New York, Michigan, Louisiana, Pennsylvania and Arkansas.
Danish researchers are claiming that the benefits of breast cancer screening are questionable and that mammograms can lead to women being given unnecessary and harmful treatment.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.
› Verified 8 days ago
| Entity Name | Vision Institute Of Michigan Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396818373 PECOS PAC ID: 6800781436 Enrollment ID: O20040220000837 |
News Archive
Johns Hopkins Kimmel Cancer Center scientists report that sharp rises in levels of reactive oxygen molecules, and the inflammation that results, trigger biochemical changes that silence genes in a pattern often seen in cancer cells. The researchers confirmed this gene-silencing effect in mice that develop inflammation-induced colon cancer.
A selection of health policy stories from Florida, Connecticut, New York, Michigan, Louisiana, Pennsylvania and Arkansas.
Danish researchers are claiming that the benefits of breast cancer screening are questionable and that mammograms can lead to women being given unnecessary and harmful treatment.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.
› Verified 8 days ago
| Entity Name | University Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447299797 PECOS PAC ID: 8628087681 Enrollment ID: O20060419000518 |
News Archive
Johns Hopkins Kimmel Cancer Center scientists report that sharp rises in levels of reactive oxygen molecules, and the inflammation that results, trigger biochemical changes that silence genes in a pattern often seen in cancer cells. The researchers confirmed this gene-silencing effect in mice that develop inflammation-induced colon cancer.
A selection of health policy stories from Florida, Connecticut, New York, Michigan, Louisiana, Pennsylvania and Arkansas.
Danish researchers are claiming that the benefits of breast cancer screening are questionable and that mammograms can lead to women being given unnecessary and harmful treatment.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Faisal M Almufarrej, MD 1560 E Maple Rd, Suite 400-credentialing, Troy, MI 48083-1138 Ph: (248) 581-5974 | Dr Faisal M Almufarrej, MD 3901 Beaubien St, Detroit, MI 48201-2119 Ph: (313) 745-0247 |
News Archive
Johns Hopkins Kimmel Cancer Center scientists report that sharp rises in levels of reactive oxygen molecules, and the inflammation that results, trigger biochemical changes that silence genes in a pattern often seen in cancer cells. The researchers confirmed this gene-silencing effect in mice that develop inflammation-induced colon cancer.
A selection of health policy stories from Florida, Connecticut, New York, Michigan, Louisiana, Pennsylvania and Arkansas.
Danish researchers are claiming that the benefits of breast cancer screening are questionable and that mammograms can lead to women being given unnecessary and harmful treatment.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.
› Verified 8 days ago
Kaitlyn Dobesh, MD Surgery Medicare: Medicare Enrolled Practice Location: 2799 W Grand Blvd, Detroit, MI 48202 Phone: 313-916-2600 | |
Dr. Bellal Ali Joseph, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2799 W Grand Blvd, Detroit, MI 48202 Phone: 313-916-3056 Fax: 313-916-9920 | |
Charles Edward Lucas, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4160 John R St, Suite 615, Detroit, MI 48201 Phone: 313-745-4195 Fax: 313-993-8669 | |
Christopher Paul Cassell, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 22101 Moross Rd, Detroit, MI 48236 Phone: 313-343-4000 | |
Mitchell Ross Weaver, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2799 W Grand Blvd, Detroit, MI 48202 Phone: 313-916-3156 Fax: 313-916-3023 | |
Alexander Marinica, Surgery Medicare: Accepting Medicare Assignments Practice Location: 6071 W Outer Dr Ste 121, Detroit, MI 48235 Phone: 313-966-3222 | |
Dr. Rachel Wobig, MD Surgery Medicare: Medicare Enrolled Practice Location: 2799 W Grand Blvd, Detroit, MI 48202 Phone: 313-916-5071 Fax: 313-916-9920 |